Fundraising FoxLondon · Seed–Late Stage · 20 people tracked
Also known as MVM PARTNERS LLP · MVM PARTNERS, LLC
Find your way into MVM Life Science Partners
Each arrow is one introduction. Sign up to fill in the first one.
Ask Laurent Vernier to introduce you to Eric Fritz
You →Laurent · together at Pléiade Venture →Eric
Ask Jamie Chen to introduce you to Kevin Cheng
You →Jamie · together at Paragon28 →Kevin
Ask Sam Okafor to introduce you to Hugo Harrod
You →Sam · together at ProVerum →Hugo
- Akhilesh Pathipati306 people can intro you
- Kyle Dempsey269 people can intro you
- Neil Akhurst264 people can intro you
Sign up to find every way you can get introduced to MVM Life Science Partners
- Your email: who you already know at MVM Life Science Partners, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the MVM Life Science Partners team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Investment thesis
MVM invests broadly across healthcare and life sciences, providing equity to high-growth companies with differentiated products or technologies. It targets businesses addressing significant unmet needs in large addressable markets, such as untreated medical conditions, overly expensive therapies, or diagnostic gaps, favoring durable competitive protection through IP, market-entry barriers, statutory exclusivity, or branding. The firm partners closely with management teams to accelerate growth, drive strategic acquisitions, and establish new standards of care. It maintains a concentrated portfolio and typically deploys aggregate investments of $20-100 million per company over the holding period, with capacity for larger commitments in select creative financing situations.
Source: firm website, verified Sep 29, 2026.
Team · 20 people
from the firm's website & public directories
What they invest in
from 22 of 23 portfolio companiesHealthtech ×20Medical Devices ×14Biotech ×10Hardware ×5Advanced Manufacturing ×1FemTech ×1New Materials ×1
HQs:United States×18Ireland×1Netherlands×1
Investments · 23 tracked
founders shown can be your intro pathBy year:2026 · 12025 · 22024 · 12023 · 32022 · 12021 · 22020 · 12019 · 22017 · 12016 · 22015 · 218 dated
BioProtect develops a balloon spacer device for brachytherapy procedures, used to create spacing during cancer radiation treatment.
BiotechHealthtechMedical Devices
Itay Barnea(Chief Executive Officer)inDerek Webster(Chief Commercial Officer)inLee Adler(Chief Operating Officer)inShahar Shaked(Chief Financial Officer)inDafna Carmi-Yinon(Chief Product and Clinical Officer)in
Co-investorsAlmeda VenturesTriventuresOlympus Innovation VenturesPeregrine VenturesXenia Venture Capital
AccuVein manufactures vein visualization systems for medical professionals to locate veins during procedures.
HardwareHealthtechMedical DevicesCold Spring Harbor, US
Ron Goldman(Executive Officer, Director)inChris Hutchison(President & CEO)in
BoardJames Lackie(Director)Eric Bednarski(Director)Frank Flaut III(Director)Christopher Gabrieli(Director)
Board seatStephen ReedersAkhilesh Pathipati· per SEC Form D
Co-investorsBessemer Venture Partners
Leader in non-invasive cardiac output and hemodynamic monitoring with its CHEETAH NICOM system; based in Newton, MA with offices in Tel-Aviv and Portland.
HealthtechNewton, US
Christopher Hutchison(Executive Officer, Director)inKevin McArdle(Executive Officer)Yuval Rozen(Executive Officer)
BoardSteven Reeders(Director)Renard Charity(Director)inAnthony Moshal(Director)
Board seatStephen Reeders· per SEC Form D
Co-investorsAscension VenturesBosch VenturesHighCape CapitalRobert Bosch Venture Capital
CurvaFix develops the CurvaFix Low Profile intramedullary nailing system, curved implants for surgical stabilization of pelvic fractures.
HardwareHealthtechMedical DevicesBellevue, US
Jeffrey Poole(Executive Officer)Mark Foster(Executive Officer, Director)inSteven Dimmer(Executive Officer, Director, Promoter)Dong-Gun Kim(Director)
Board seatJack TanakaEric Fritz· per SEC Form D
Co-investorsAlliance of AngelsRockies Venture ClubSPRINGROCK VENTURESSwan Venture FundKeiretsu CapitalSectoral Asset Management+1 more
FemTechHealthtechMedical DevicesRedwood City, US
Christopher Owens(Executive Officer, Director)Darrin Uecker(Executive Officer, Director)
BoardKen Haas(Director)Jonathan MacQuitty(Director)inMike Carusi(Director)inDoug Fisher(Director)
Board seatHugo Harrod· per SEC Form D · $92.2M raise · filed Nov 2023
Co-investorsAmzak HealthBain Capital Life SciencesEndeavour VisionFemHealth VenturesKaiser Permanente VenturesKluz Ventures+6 more
Nalu Medical develops a non-integrated neurostimulation system that uses electrical impulses to interrupt pain signals for patients with intractable chronic nerve pain.
HardwareHealthtechMedical DevicesCarlsbad, US
Earl Fender(President & CEO)inLee Hartley(Executive Officer)inAllen Meacham(Executive Officer)inBick Sellers(Executive Officer)inThomas A. West(Executive Officer, Director)inJeffrey Swiecki(Executive Officer)
Board seatHugo Harrod· per SEC Form D
Co-investorsAPERTURE Venture PartnersB Capital GroupB4 CapitalDecheng CapitalEndeavour VisionLongitude Capital+3 more
.jpeg){kind=logo}
Optinose is a specialty pharmaceutical company that develops and markets products for patients with conditions treated by ear, nose, and throat (ENT) and allergy specialists.
BiotechHealthtechMedical DevicesYardley, US
Per Djupesland(Executive Officer, Director)inMichele Janis(Executive Officer)Peter Miller(Executive Officer, Director)inTerrence Terifay(Executive Officer)Ramy Mahmoud(Executive Officer)in
BoardKlaas De Boer(Director)
Board seatEric BednarskiKyle Dempsey· per SEC Form D · $4.7M raise · filed May 2024
Co-investorsAvistaForesite Capital
Tarsa Therapeutics developed TBRIA, an oral formulation of calcitonin for treating postmenopausal osteoporosis in women more than five years post menopause when other treatments are unsuitable.
BiotechPhiladelphia, US
David Brand(Executive Officer, Director)inGregory Lumpkin(Executive Officer)
BoardRichard Kollender(Director)Martin Edwards(Director)Derek Ferguson(Director)
Board seatEric Bednarski· per SEC Form D
Co-investorsForesite CapitalOxford Finance LLCQuaker BioVentures
Vertos Medical (part of Stryker's Interventional Spine business) develops minimally invasive interventional treatments for chronic pain and reduced mobility, including vertebral augmentation, bone tumor ablation, and basivertebral nerve ablation.
HealthtechMedical DevicesAliso Viejo, US
Eric Wichems(Executive Officer, Director)inRebecca Colbert(Executive Officer)in
BoardMyles Greenberg(Director)Daniel Pelak(Director)Ittai Harel(Director)inJohn Ryan(Director)
Board seatHugo Harrod· per SEC Form D
Co-investorsNorwest Venture PartnersPitango
HealthtechCampbell, US
Nersi Nazari(Executive Officer, Director)inSteve Zadig(Executive Officer, Director)in
BoardRichard Feachem(Director)Tom Saunders(Director)
Board seatStephen Reeders· per SEC Form D · $38.1M raise · filed Oct 2017
Co-investorsAsahi Kasei Corporate Venture CapitalEssex Woodlands Healthcare PartnersRevelation PartnersAlly Bridge GroupTrinity Capital
Innovator in non-invasive surgical skin closure devices used in over 100,000 cases across 30+ countries; headquartered in Campbell, CA.
Campbell, US
Amir Belson(Director)John Tighe(Executive Officer, Director)in
BoardPatrick Berbon(Director)Balaji Muralidhar(Director)
Board seatStephen Reeders· per SEC Form D · $26.9M raise · filed Jan 2016
Co-investorsClaremont Creek VenturesHighCape CapitalXSeed Capital
AmbioPharm is a contract manufacturer of custom peptide active pharmaceutical ingredients (APIs), providing process development, scale-up, and cGMP manufacturing for late-stage clinical and commercial peptide products.
Advanced ManufacturingBiotechHealthtechNorth Augusta, US
Avanzanite is a biopharmaceutical commercialization and distribution company that partners with emerging research-based drug originators to license and distribute approved orphan (rare disease) medicines across European markets.
BiotechHealthtechAmsterdam, NL
Adam Plich(Founder, CEO & Executive Board Member)inAnant Murthy(Founder & Board Member)Abdel Omari(Chief Financial Officer & Executive Board Member)in
Biotheranostics develops proprietary genomic assays used to support personalized disease management in oncology.
BiotechHealthtechMedical DevicesSan Diego, US
Nicholas Barthelemy(Executive Officer, Director, Promoter)
BoardDavid Kabakoff(Director)inEric Bednarski(Director)Alejandro Sanchez(Director)in
Co-investorsEvidity Health CapitalHealthQuest Capital
GammaTile is an FDA-cleared, bioresorbable collagen tile embedded with radiation sources that is implanted during brain tumor removal surgery to deliver targeted radiation to remaining cancer cells.
BiotechHealthtechMedical Devices
David G. Brachman, MD, FASTRO(Co-Founder and Chief Technology Officer)Heyoung McBride, MD, MS, FASTRO(Co-Founder)Peter Nakaji, MD(Co-Founder)inEmad Youssef, MD(Co-Founder)Theresa Thomas, MS, CCRC(Co-Founder)Per Langoe(Chief Executive Officer)in
Co-investorsAccelmed PartnersBlueStone Venture PartnersEvidity Health CapitalFemHealth VenturesGilde HealthcareMedTech Venture Partners
Neurent Medical develops the NEUROMARK system, a radiofrequency ablation device that targets hyperactive autonomic nerves to treat chronic rhinitis symptoms in ENT patients.
HardwareHealthtechMedical Devices
Co-investorsAtlantic Bridge VenturesClaret Capital PartnersFountain Healthcare PartnersSofinnova PartnersEnterprise IrelandEQT Life Sciences+1 more
OSSIO develops OSSIOfiber, a bio-integrative bone fixation implant material made from natural mineral fibers that provides stability during healing and integrates fully into bone over 18-24 months, avoiding permanent metal hardware.
BiotechHealthtechMedical DevicesNew MaterialsPalmetto, US
Orahn Preiss-Bloom(Founder & Chief Innovation Officer)inBrian Verrier(Chief Executive Officer)inBrennan Marilla(Chief Commercial and Operating Officer)inMoshe Shneor(Chief Financial Officer)inGregory C. Berlet(Chief Medical Officer)
Co-investorsOCV PartnersQuesta CapitalSecocha Ventures
ProVerum is a venture-backed medical device startup developing minimally invasive technologies to treat benign prostatic hyperplasia (BPH).
HardwareHealthtechMedical DevicesDublin, IE
Dr Conor Harkin(Founder)inRíona Ní Ghriallais(Founder)in
Co-investorsAtlantic Bridge VenturesIreland Strategic Investment FundLightstone VenturesOrbiMed
HealthtechIrvine, US
Kenny Chang(Executive Officer)W. Ronald Redmond(Director)Vijay Dhaka(Executive Officer)Philong Pham(Executive Officer, Director)Hongsheng Tong(Executive Officer, Director)
Co-investorsBlackRockEndeavour VisionRTW Investments L.P.Soleus CapitalvenBio Global StrategicVivo Capital
Urotronic develops drug-coated balloons for interventional urology, including the Optilume products for treating benign prostatic hyperplasia (BPH) and urethral strictures.
HealthtechMedical DevicesPlymouth, US
Junfeng Wang(Director)David Perry(Executive Officer, Director)Tan Ching(Director)Hui Hu(Director, Promoter)Lixiao Wang(Director, Promoter)Doug Kohrs(Director)
Co-investorsHM Venture PartnersEnterprise IrelandGilde HealthcareIreland Strategic Investment FundLegend CapitalLightstone Ventures+1 more
VERO Biotech develops next-generation inhaled nitric oxide (iNO) delivery systems for patients with cardiopulmonary conditions in acute care hospital settings.
BiotechHealthtechMedical Devices
Co-investorsBrace PharmaRunway Growth Capital
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 1
1 acquisitionsGynesonicsacq. by Hologic
Portfolio news
latest coverage across their companiesOssio · finance.yahoo.com · Jul 6, 2026
AmbioPharm · scbiz.com · Jun 16, 2026
Nalu · trysignalbase.com · Mar 25, 2026
Neurent Medical · finance.yahoo.com · Feb 12, 2026
Avanzanite · finsmes.com · Nov 18, 2025
ProVerum · eu-startups.com · Aug 26, 2025
Frequently asked questions
- How many investments has MVM Life Science Partners made?
- MVM Life Science Partners has 23 tracked investments, 1 of which have exited, including 3 dated in the last 24 months.
- What stage does MVM Life Science Partners invest at?
- MVM Life Science Partners invests at the Seed, Series A, Growth, Late Stage stages.
- What is MVM Life Science Partners's typical check size?
- MVM Life Science Partners typically writes checks of $20M – $100M.
- What sectors does MVM Life Science Partners focus on?
- MVM Life Science Partners focuses on Biotech, Digital Health, Healthtech, Longevity, Medical Devices.
- Where is MVM Life Science Partners located?
- MVM Life Science Partners is headquartered in London, GB.
- Who does MVM Life Science Partners co-invest with?
- MVM Life Science Partners most often shares deals with Atlantic Bridge Ventures, B Capital Group, Lightstone Ventures, among 26 tracked co-investors.
Similar investors
GV (Google Ventures) is a venture capital firm that has invested in AI and machine learning since its early days, backing more than 100 AI companies across infrastructure, life sciences, and applications.
Khosla Ventures is a venture capital firm that backs bold, early-stage, technology-driven companies across deep tech and other sectors, providing hands-on 'venture assistance' to help founders build category-defining businesses.
EQT Life Sciences (formerly LSP) is one of Europe's largest and most experienced life sciences investors, backing companies developing therapeutics, medical devices, diagnostics and healthtech globally.
5AM Ventures is a life science venture capital firm founded in 2002 that funds and builds next-generation life sciences companies, focusing on biopharmaceuticals, drug delivery technologies, and life science instruments.
ARTIS Ventures is a venture capital firm investing in breakthrough companies at the convergence of technology and biology, with a focus on healthcare and life sciences ('TechBio'). It backs founders across biotech, therapeutics, digital health, and frontier technologies.